ConductScience.org, home

Paper39154158

Perfusate Flow Rate: An Overlooked Factor in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?

Theile D and 1 other. Ann Surg Oncol, 2024. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Perfusate Flow Rate: An Overlooked Factor in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)? Papers, record 39154158. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39154158

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Perfusate Flow Rate: An Overlooked Factor in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?
PubMed
Journal
Ann Surg Oncol
PubMed
Year
2024
PubMed
Publication types
Letter
PubMed
Citations, by iCite
0
iCite
Relative citation ratio, by iCite
0.0, provisional
iCite
Revised in PubMed
2024-11-11
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Theile DDirkhttps://orcid.org/0000-0003-4720-9242
2Czock DDavid

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References9

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130911633Pharmacological principles of intraperitoneal and bidirectional chemotherapy.Pleura Peritoneum2017https://conductscience.org/library/papers/30911633PubMed
210197298Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.J Clin Pharmacol1999https://conductscience.org/library/papers/10197298PubMed
325171494Higher flow rates improve heating during hyperthermic intraperitoneal chemoperfusion.J Surg Oncol2014https://conductscience.org/library/papers/25171494PubMed
49178181Oral sustained-release cisplatin preparation for rats and mice.J Pharm Pharmacol1997https://conductscience.org/library/papers/9178181PubMed
515258698Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.Cancer Chemother Pharmacol2005https://conductscience.org/library/papers/15258698PubMed
628273222Exploring flow rate selection in HIPEC procedures.Rev Col Bras Cir2016https://conductscience.org/library/papers/28273222PubMed
739037523The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: HIPEC Technologies.Ann Surg Oncol2024https://conductscience.org/library/papers/39037523PubMed
835325402The Role of Hyperthermia in the Treatment of Peritoneal Surface Malignancies.Curr Oncol Rep2022https://conductscience.org/library/papers/35325402PubMed
921251871Drug transporters of platinum-based anticancer agents and their clinical significance.Drug Resist Updat2011https://conductscience.org/library/papers/21251871PubMed

Download CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CYP4F34051PubTator's text mininghttps://conductscience.org/library/genes/4051

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39154158

GET https://conductscience.org/api/papers/v1/39154158/authors